Key result
Paclitaxel-eluting balloons linked to ~42-point lower 3-month restenosis vs historical controls in infrapopliteal lesions.
Why the study?
Restenosis rates for long-segment tibial artery disease treated with standard balloon angioplasty are very high, motivating this investigation into the efficacy of drug-eluting balloons for long infrapopliteal lesions.
Does infrapopliteal angioplasty with a paclitaxel-eluting balloon reduce 3-month binary restenosis and improve 12-month clinical outcomes in patients with long infrapopliteal lesions?
Observational (n=104)
Does infrapopliteal angioplasty with a paclitaxel-eluting balloon reduce 3-month binary restenosis and improve 12-month clinical outcomes in patients with long infrapopliteal lesions?
Paclitaxel-eluting balloon angioplasty for long-segment infrapopliteal disease demonstrated a 27.4% 3-month restenosis rate and 95.6% midterm limb salvage in critical limb ischemia, comparing favorably to historical uncoated balloon data.
Hypothesis-generating for paclitaxel-eluting balloons in infrapopliteal CLI; leaves open randomized confirmation of restenosis and limb salvage benefits.
Objectives The purpose of this study was to investigate the efficacy of drug-eluting balloons (DEBs) in the treatment of long infrapopliteal lesions with regard to the short-term restenosis rate and midterm clinical result. Background Restenosis rates of long-segment tibial artery disease are very high. Recently, a restenosis rate of 69% at 3 months after standard balloon angioplasty was demonstrated. Methods Infrapopliteal angioplasty was performed with a paclitaxel-eluting balloon (In.Pact Amphirion, Medtronic, Minneapolis, Minnesota). Clinical and angiographic follow-up was performed at 3 months to detect binary restenosis, and further clinical assessment was performed over a 12-month period thereafter. Results In 104 patients, 109 limbs were treated for critical limb ischemia (82.6%) or severe claudication (17.4%). Mean lesion length of the arteries treated was 176 ± 88 mm. Angiography studied in 84 treated arteries at 3 months showed a restenosis in 27.4% (19.1% had restenosis of more than 50%, and 8.3% were totally occluded) and usually occurred focally. Only in 9.5% of all angiographically followed up arteries was the entire treated segment restenosed or reoccluded. During a follow-up period of 378 ± 65 days, 1 patient was lost and 17 died. Of the 91 limbs remaining in the analysis, clinical improvement was present in 83 (91.2%). Complete wound healing occurred in 74.2%, whereas major amputation occurred in 4 patients, resulting in limb salvage of 95.6% for patients with critical limb ischemia. Conclusions The early restenosis rate of long-segment infrapopliteal disease is significantly lower after treatment with DEBs compared with historical data using uncoated balloons. Randomized trials are required to show whether this difference will lead to improvement in clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2011) conducted an observational in Long infrapopliteal artery lesions with critical limb ischemia or severe claudication (n=104). Paclitaxel-eluting balloon angioplasty (In.Pact Amphirion) vs. Historical control (standard uncoated balloon angioplasty) was evaluated on Angiographic binary restenosis at 3 months. Paclitaxel-eluting balloon angioplasty in long infrapopliteal lesions resulted in a 27.4% 3-month restenosis rate (vs 69% in historical uncoated balloon controls) and 91.2% clinical improvement.
Synapse has enriched 5 related papers. Consider them for comparative context: